In contrast, systemic deletion of Akt1 or Akt2 in mice increases mortality, due to significant disruptions in circulating glucose and insulin levels, resulting in hyperglycemia, which is notably a known adverse effect of pan-AKT inhibitors in the clinic [198]. This evidence concerns the gene AKT1 and Hyperglycemia.